TR201901422T4 - Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri. - Google Patents
Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri. Download PDFInfo
- Publication number
- TR201901422T4 TR201901422T4 TR2019/01422T TR201901422T TR201901422T4 TR 201901422 T4 TR201901422 T4 TR 201901422T4 TR 2019/01422 T TR2019/01422 T TR 2019/01422T TR 201901422 T TR201901422 T TR 201901422T TR 201901422 T4 TR201901422 T4 TR 201901422T4
- Authority
- TR
- Turkey
- Prior art keywords
- treatment
- cortexolone
- diesters
- tumors
- metaplasias
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 title abstract 2
- 206010058314 Dysplasia Diseases 0.000 abstract 1
- 206010054949 Metaplasia Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000015689 metaplastic ossification Effects 0.000 abstract 1
- 238000009099 neoadjuvant therapy Methods 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Mevcut buluş, belirli korteksolon (cortexolone) türevlerini sağlamaktadır ve bunlar prekanseröz lezyonların, displazilerin, metaplazilerin ve malign neoplaziler ve metastaz dahil tümör hastalıklarının küratif veya adjuvan ya da neoadjuvan veya palyatif tedavisinde antitümör aktif bileşenler olarak kullanım içindir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14188063.3A EP3006453A1 (en) | 2014-10-08 | 2014-10-08 | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201901422T4 true TR201901422T4 (tr) | 2019-02-21 |
Family
ID=51687868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/01422T TR201901422T4 (tr) | 2014-10-08 | 2015-10-07 | Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri. |
Country Status (23)
Country | Link |
---|---|
US (7) | US10183030B2 (tr) |
EP (4) | EP3006453A1 (tr) |
JP (5) | JP6735739B2 (tr) |
KR (4) | KR20230052990A (tr) |
CN (5) | CN107001406B (tr) |
AU (3) | AU2015329999B2 (tr) |
BR (2) | BR112017007078A2 (tr) |
CA (3) | CA2960928C (tr) |
DK (2) | DK3456330T3 (tr) |
ES (3) | ES2713699T3 (tr) |
HR (2) | HRP20190194T1 (tr) |
HU (2) | HUE055143T2 (tr) |
IL (3) | IL272095B2 (tr) |
LT (2) | LT3204400T (tr) |
MX (3) | MX2017004661A (tr) |
PL (2) | PL3204400T3 (tr) |
PT (2) | PT3456330T (tr) |
RS (2) | RS62147B1 (tr) |
RU (2) | RU2712950C2 (tr) |
SI (2) | SI3204400T1 (tr) |
TR (1) | TR201901422T4 (tr) |
WO (2) | WO2016055533A1 (tr) |
ZA (2) | ZA201702209B (tr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
KR102342620B1 (ko) | 2017-03-31 | 2021-12-22 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제 |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
KR102657097B1 (ko) | 2018-12-19 | 2024-04-15 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제 |
CN110698527B (zh) * | 2019-11-19 | 2022-08-26 | 湖南新合新生物医药有限公司 | 一种高纯度氢化可的松-17-戊酸酯的制备方法 |
CN112028956A (zh) * | 2020-09-10 | 2020-12-04 | 那路新 | 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法 |
CN114113603B (zh) * | 2021-06-30 | 2023-11-17 | 四川大学华西医院 | Cytl1作为胃癌预后标志物的应用 |
WO2023088308A1 (zh) * | 2021-11-16 | 2023-05-25 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE619180A (fr) * | 1961-06-24 | 1962-12-20 | Vismara Francesco Spa | 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation |
CH429716A (de) * | 1961-06-24 | 1967-02-15 | Vismara Francesco Spa | Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden |
NL6605514A (tr) | 1966-04-25 | 1967-10-26 | ||
DE2748442C3 (de) | 1977-10-26 | 1981-08-27 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel |
EP0001737B1 (de) | 1977-10-26 | 1981-01-07 | Schering Aktiengesellschaft | 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung |
ATE12237T1 (de) * | 1980-12-23 | 1985-04-15 | Schering Ag | Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung. |
DE3260474D1 (en) | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
US4920216A (en) * | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
CA2025670A1 (en) | 1989-02-07 | 1990-08-08 | Bruce A. Pearlman | 9.alpha.-dehalogenation of steroids using tin or lead |
DE4121484A1 (de) | 1991-06-26 | 1993-01-07 | Schering Ag | Verfahren zur herstellung von 6-methylensteroiden |
US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
PT1183014E (pt) | 1999-06-14 | 2003-12-31 | Cosmo Spa | Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
CA2428799A1 (en) | 2000-11-16 | 2002-05-23 | Alcon Manufacturing, Ltd. | Combination therapy for lowering and controlling intraocular pressure |
ITMI20011762A1 (it) * | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
ITMI20051695A1 (it) * | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
DE102006059063A1 (de) | 2005-12-24 | 2007-06-28 | Bayer Healthcare Ag | Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074 |
US7687484B2 (en) | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
ITMI20071616A1 (it) * | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
CN101397317A (zh) | 2007-09-27 | 2009-04-01 | 天津药业研究院有限公司 | 一种新型硝酸酯类甾体化合物 |
AU2008335469A1 (en) * | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US20090240049A1 (en) | 2008-03-18 | 2009-09-24 | Marco Villa | Purification of air sensitive steroids |
EP3546945A1 (en) * | 2010-06-01 | 2019-10-02 | Metanomics Health GmbH | Means and methods for diagnosing pancreatic cancer in a subject |
EP2701744A4 (en) * | 2011-03-23 | 2014-08-20 | Pop Test Cortisol Llc | COMBINATION THERAPY |
RU2506974C1 (ru) | 2012-11-06 | 2014-02-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения первично нерезектабельного рака легкого |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
EP3006453A1 (en) * | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
-
2014
- 2014-10-08 EP EP14188063.3A patent/EP3006453A1/en not_active Withdrawn
-
2015
- 2015-10-07 KR KR1020237011743A patent/KR20230052990A/ko not_active Application Discontinuation
- 2015-10-07 PL PL15778634T patent/PL3204400T3/pl unknown
- 2015-10-07 HU HUE18198653A patent/HUE055143T2/hu unknown
- 2015-10-07 SI SI201530614T patent/SI3204400T1/sl unknown
- 2015-10-07 AU AU2015329999A patent/AU2015329999B2/en active Active
- 2015-10-07 WO PCT/EP2015/073172 patent/WO2016055533A1/en active Application Filing
- 2015-10-07 RU RU2017115771A patent/RU2712950C2/ru active
- 2015-10-07 BR BR112017007078A patent/BR112017007078A2/pt not_active Application Discontinuation
- 2015-10-07 PL PL18198653T patent/PL3456330T3/pl unknown
- 2015-10-07 KR KR1020177011114A patent/KR102248983B1/ko active IP Right Grant
- 2015-10-07 EP EP18198653.0A patent/EP3456330B1/en active Active
- 2015-10-07 RU RU2017115773A patent/RU2712752C2/ru active
- 2015-10-07 KR KR1020217002286A patent/KR102520411B1/ko active IP Right Grant
- 2015-10-07 CN CN201580060690.2A patent/CN107001406B/zh active Active
- 2015-10-07 ES ES15778634T patent/ES2713699T3/es active Active
- 2015-10-07 CA CA2960928A patent/CA2960928C/en active Active
- 2015-10-07 CA CA2962746A patent/CA2962746A1/en not_active Abandoned
- 2015-10-07 BR BR112017007076-6A patent/BR112017007076B1/pt active IP Right Grant
- 2015-10-07 EP EP15775455.7A patent/EP3204012B1/en active Active
- 2015-10-07 US US15/517,653 patent/US10183030B2/en active Active
- 2015-10-07 IL IL272095A patent/IL272095B2/en unknown
- 2015-10-07 HU HUE15778634A patent/HUE041503T2/hu unknown
- 2015-10-07 MX MX2017004661A patent/MX2017004661A/es unknown
- 2015-10-07 WO PCT/EP2015/073176 patent/WO2016055537A1/en active Application Filing
- 2015-10-07 LT LTEP15778634.4T patent/LT3204400T/lt unknown
- 2015-10-07 RS RS20210928A patent/RS62147B1/sr unknown
- 2015-10-07 PT PT181986530T patent/PT3456330T/pt unknown
- 2015-10-07 ES ES15775455T patent/ES2806094T3/es active Active
- 2015-10-07 EP EP15778634.4A patent/EP3204400B1/en active Active
- 2015-10-07 DK DK18198653.0T patent/DK3456330T3/da active
- 2015-10-07 KR KR1020177011239A patent/KR20170063821A/ko unknown
- 2015-10-07 AU AU2015330003A patent/AU2015330003A1/en not_active Abandoned
- 2015-10-07 DK DK15778634.4T patent/DK3204400T3/en active
- 2015-10-07 TR TR2019/01422T patent/TR201901422T4/tr unknown
- 2015-10-07 CN CN201580060711.0A patent/CN107074905B/zh not_active Expired - Fee Related
- 2015-10-07 PT PT15778634T patent/PT3204400T/pt unknown
- 2015-10-07 US US15/517,659 patent/US10231980B2/en active Active
- 2015-10-07 CN CN202010134553.1A patent/CN111285913B/zh active Active
- 2015-10-07 MX MX2017004660A patent/MX366294B/es active IP Right Grant
- 2015-10-07 CA CA3160391A patent/CA3160391C/en active Active
- 2015-10-07 LT LTEP18198653.0T patent/LT3456330T/lt unknown
- 2015-10-07 SI SI201531666T patent/SI3456330T1/sl unknown
- 2015-10-07 ES ES18198653T patent/ES2882223T3/es active Active
- 2015-10-07 RS RS20190207A patent/RS58607B1/sr unknown
- 2015-10-07 JP JP2017518978A patent/JP6735739B2/ja active Active
- 2015-10-07 CN CN202211571443.7A patent/CN116102604A/zh active Pending
- 2015-10-07 JP JP2017518340A patent/JP6503057B2/ja active Active
- 2015-10-07 CN CN202211425819.3A patent/CN115671114A/zh active Pending
-
2017
- 2017-03-08 IL IL251028A patent/IL251028B/en active IP Right Grant
- 2017-03-23 IL IL251371A patent/IL251371A0/en unknown
- 2017-03-29 ZA ZA2017/02209A patent/ZA201702209B/en unknown
- 2017-04-07 MX MX2019008063A patent/MX2019008063A/es unknown
-
2018
- 2018-11-23 US US16/199,015 patent/US10646497B2/en active Active
-
2019
- 2019-01-17 JP JP2019006199A patent/JP7028809B2/ja active Active
- 2019-01-29 HR HRP20190194TT patent/HRP20190194T1/hr unknown
- 2019-02-12 US US16/273,575 patent/US20190175618A1/en not_active Abandoned
- 2019-04-12 ZA ZA2019/02320A patent/ZA201902320B/en unknown
-
2020
- 2020-02-27 AU AU2020201446A patent/AU2020201446B2/en active Active
- 2020-03-16 US US16/820,407 patent/US10993949B2/en active Active
- 2020-05-27 JP JP2020092411A patent/JP2020143140A/ja active Pending
- 2020-12-01 JP JP2020199555A patent/JP2021046418A/ja active Pending
-
2021
- 2021-04-06 US US17/223,776 patent/US11712443B2/en active Active
- 2021-07-22 HR HRP20211177TT patent/HRP20211177T1/hr unknown
-
2022
- 2022-12-19 US US18/068,346 patent/US11986484B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201901422T4 (tr) | Tümörlerin tedavisinde kullanım için korteksolon 17A,21-diesterleri. | |
MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
EA201591823A1 (ru) | Ингибиторы ido | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
MX2015011374A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
CY1122243T1 (el) | Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt | |
TW201613901A (en) | New compounds | |
MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
EA201690027A1 (ru) | Ингибиторы ido | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
AU2015237050A8 (en) | Quinoline derivatives as SMO inhibitors | |
PH12017500215A1 (en) | Protein kinase c inhibitors and methods of their use | |
BR112016004194A8 (pt) | compostos úteis como imunomoduladores | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
MX2018010993A (es) | Derivados de icariina e icaritina. | |
MX2016009663A (es) | Derivados de icariina. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
EA201691896A1 (ru) | Соединения и способы их применения | |
EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
EA201992022A1 (ru) | Терапевтическая рнк |